Stockscreener 앱 받기
24.43
1.12%
0.27
시간 외 거래:
24.35
-0.08
-0.33%
전일 마감가:
$24.16
열려 있는:
$24.14
하루 거래량:
1.58M
Relative Volume:
0.84
시가총액:
$2.66B
수익:
-
순이익/손실:
$-237.54M
주가수익비율:
-9.7591
EPS:
-2.5033
순현금흐름:
$-145.05M
1주 성능:
+5.12%
1개월 성능:
+16.39%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$24.10
$25.02
1주일 범위
$22.86
$25.23
52주 변동 폭
$14.62
$26.25
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
24.43 | 2.59B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics Announces New Employee Inducement GrantsJune 15, 2026 - BioSpace
Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan
Definium Therapeutics (DFTX) director awarded RSUs and stock options in new grant - Stock Titan
Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and stock options in equity award - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and 19,188 stock options - Stock Titan
Six new Definium hires receive options on 155,480 shares - Stock Titan
Definium Therapeutics, Inc. Announces 2026 Annual Meeting Results and Key SEC Filings - Minichart
Definium Therapeutics (NASDAQ: DFTX) OKs 5M-share equity plan boost - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Approaching DT120 Phase III Readouts At Definium Therapeutics (DFTX) Have Changed Its Investment Story - Sahm
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
DFTX: Director elections, auditor appointment, and equity plan amendment approved; clinical trial results expected late Q2 - TradingView
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum - Yahoo Finance
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com Nigeria
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $44 - Moomoo
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart | Capital.com UAE - Capital.com
Definium Therapeutics nears key depression drug trial results - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - Yahoo Finance
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (DFTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
2.60%
0.94%
자본화:
|
볼륨(24시간):